Antigen Information

General Information of This Antigen

Antigen ID	TAR0YLQCG
Antigen Name	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
Gene Name	CD38
Synonym	2'-phospho-ADP-ribosyl cyclase;2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase;2'-phospho-cyclic-ADP-ribose transferase;ADP-ribosyl cyclase 1;Cyclic ADP-ribose hydrolase 1;T10;CD_antigen=CD38
Sequence	MANCEFSPVSGDKPCCRLSRRAQLCLGVSILVLILVVVLAVVVPRWRQQWSGPGTTKRFP ETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCNITEEDYQPLMKLGTQTVPCN KILLWSRIKDLAHQFTQVQRDMFTLEDTLLGYLADDLTWCGEFNTSKINYQSCPDWRKDC SNNPVSVFWKTVSRRFAEAACDVVHVMLNGSRSKIFDKNSTFGSVEVHNLQPEKVQTLEA WVIHGGREDSRDLCQDPTIKELESIISKRNIQFSCKNIYRPDKFLQCVKNPEDSSCTSEI Click to Show/Hide
Family	Thymidylate 5'-phosphatase family
Function	Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+). Has cADPR hydrolase activity. Click to Show/Hide
Uniprot Entry	CD38_HUMAN
HGNC ID	HGNC:1667
KEGG ID	hsa:952

Each Antibody-drug Conjuate AND It's Component Related to This Antigen

Full List of The ADC Related to This Antigen

alpha-CD38 mAb

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	TE-1146	Lenalidomide	Undisclosed	Undisclosed	[1]

Anti-CD38 mAb

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	CD38 ADC	Undisclosed	Undisclosed	Undisclosed	[2]

C38A2/C38D8

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	CN110997009BADC#40	CN110997009B ADC#40 Payload	Undisclosed	CN110997009B ADC#40 Linker	[3]
ADC Info	CN110997009BADC#41	CN110997009B ADC#41 Payload	Undisclosed	CN110997009B ADC#40 Linker	[3]
ADC Info	CN110997009BADC#42	CN110997009B ADC#42 Payload	Microtubule (MT)	CN110997009B ADC#42 Linker	[3]
ADC Info	CN110997009BADC#43	CN110997009B ADC#43 Payload	Microtubule (MT)	CN110997009B ADC#42 Linker	[3]
ADC Info	CN110997009BADC#44	Duo5	Microtubule (MT)	CN110997009B ADC#40 Linker	[3]
ADC Info	CN110997009BADC#45	Duo5	Microtubule (MT)	CN110997009B ADC#45 Linker	[3]
ADC Info	CN110997009BADC#46	Duo5	Microtubule (MT)	CN110997009B ADC#46 Linker	[3]

Daratumumab

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	αCD38-MC-I034	Amine-I034	IKZF1/3	MC
ADC Info	Dara-DVA-I030	I030	IKZF1/3	MC-DVA-PABC
ADC Info	Dara-VA-I034 (4)	I034	IKZF1/3	MC-VA
ADC Info	Dara-VA-I034 (8)	I034	IKZF1/3	MC-VA
ADC Info	EDC-8	Undisclosed	Undisclosed	Undisclosed	[4]
ADC Info	AA-A225	Undisclosed	Undisclosed	Undisclosed	[5]
ADC Info	Daratumumab-Compound (Ia)	NeoDegrader P1	Protein cereblon (CRBN)	Daratumumab-Compound (Ia) linker	[6]
ADC Info	Anti-CD38_VCGP-Dex	Dexamethasone	Undisclosed	Mal-ValCitGlyPro-OH	[7]
ADC Info	daratumumab-I-1-1	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-1-1 linker	[8]
ADC Info	daratumumab-I-2-1.76	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-2-1.76 linker	[8]
ADC Info	daratumumab-I-3-1.39	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-3-1.39 linker	[8]
ADC Info	daratumumab-I-4-0.24	Undisclosed	Undisclosed	Undisclosed	[8]
ADC Info	daratumumab-I-5-0.15	Undisclosed	Undisclosed	Undisclosed	[8]
ADC Info	daratumumab-I-6-0	Undisclosed	Undisclosed	Undisclosed	[8]
ADC Info	daratumumab-I-7-0.01	Undisclosed	Undisclosed	Undisclosed	[8]
ADC Info	daratumumab-I-8-0.04	Undisclosed	Undisclosed	Undisclosed	[8]
ADC Info	daratumumab-I-9-1.1	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-9-0.03 linker	[8]
ADC Info	daratumumab-I-9-0.06	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-9-0.03 linker	[8]
ADC Info	daratumumab-I-10-0.14	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-10-0.08 linker	[8]
ADC Info	daratumumab-I-10-0.98	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-10-0.08 linker	[8]
ADC Info	daratumumab-I-10-0.08	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-10-0.08 linker	[8]
ADC Info	daratumumab-I-11-0.14	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-11-0.05 linker	[8]
ADC Info	daratumumab-I-11-0.05	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-11-0.05 linker	[8]
ADC Info	daratumumab-I-12-1.44	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-12-1.44 linker	[8]
ADC Info	daratumumab-I-13-0.09	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-13-0.09 linker	[8]
ADC Info	daratumumab-I-14-0.29	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-14-0.29 linker	[8]
ADC Info	daratumumab-I-15-0.74	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-15-0.74 linker	[8]
ADC Info	daratumumab-I-16-0.3	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-16-0.3 linker	[8]
ADC Info	daratumumab-I-17-0.37	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-17-0.37 linker	[8]
ADC Info	daratumumab-I-18-0.15	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-18-0.04 linker	[8]
ADC Info	daratumumab-I-18-0.05	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-18-0.04 linker	[8]
ADC Info	daratumumab-I-19-0.2	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-19-0.2 linker	[8]
ADC Info	daratumumab-I-20-0.72	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-20-0.72 linker	[8]
ADC Info	daratumumab-I-21-0.18	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-21-0.18 linker	[8]
ADC Info	daratumumab-I-22--0.18	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-22--0.18 linker	[8]
ADC Info	daratumumab-I-23-0.14	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-23-0.14 linker	[8]
ADC Info	daratumumab-I-24-0.83	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-24-0.05 linker	[8]
ADC Info	daratumumab-I-24-0.05	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-24-0.05 linker	[8]
ADC Info	daratumumab-I-25-1.25	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-25-0.1 linker	[8]
ADC Info	daratumumab-I-25-0.1	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-25-0.1 linker	[8]
ADC Info	daratumumab-I-26--0.1	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-26--0.1 linker	[8]
ADC Info	daratumumab-I-27--0.02	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-27--0.02 linker	[8]
ADC Info	daratumumab-I-30-0.22	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-30-0.22 linker	[8]
ADC Info	daratumumab-I-32-0.28	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-32-0.28 linker	[8]
ADC Info	daratumumab-I-33-0.33	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-33-0.33 linker	[8]
ADC Info	daratumumab-I-35-2.05	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-35-0.3 linker	[8]
ADC Info	daratumumab-I-35-0.3	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-35-0.3 linker	[8]
ADC Info	daratumumab-I-36-5.03	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-36-5.03 linker	[8]
ADC Info	daratumumab-I-37-5.49	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-37-5.49 linker	[8]
ADC Info	daratumumab-I-38-0.52	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-38-0.31 linker	[8]
ADC Info	daratumumab-I-39-0.36	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-39-0.46 linker	[8]
ADC Info	daratumumab-I-40-0.4	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-40-0.69 linker	[8]
ADC Info	daratumumab-I-42-0.13	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-42-0.13 linker	[8]
ADC Info	daratumumab-I-43-0.26	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-43-0.26 linker	[8]
ADC Info	daratumumab-I-44-0.59	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-44-0.59 linker	[8]
ADC Info	daratumumab-I-45-0.64	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-45-0.7 linker	[8]
ADC Info	daratumumab-I-46-0.43	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-46-0.15 linker	[8]
ADC Info	daratumumab-I-46-0.15	Cetuximab-I-45-0.7 payload	Undisclosed	Daratumumab-I-46-0.15 linker	[8]

HuAT12/5

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	HuAT12/5-Compound (Ia)	NeoDegrader P1	Protein cereblon (CRBN)	HuAT12/5-Compound (Ia) linker	[6]

Indatuximab

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Indatuximab-Compound (Ia)	NeoDegrader P1	Protein cereblon (CRBN)	Indatuximab-Compound (Ia) linker	[6]
ADC Info	JP7623413B2 ExampleADC56	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	jP7560255B2 ControlADC56	Undisclosed	Undisclosed	Undisclosed	[10]

Isatuximab

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Isatuximab-Compound (Ia)	NeoDegrader P1	Protein cereblon (CRBN)	Isatuximab-Compound (Ia) linker	[6]

STI-5171

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	STI-6129	Duostatin 5.2	Microtubule (MT)	Non-polyethylene glycol linker
ADC Info	CD38-077	Duostatin 5.2	Microtubule (MT)	Non-polyethylene glycol linker	[11]

Undisclosed

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	TAK-169	Ribosome inactivating SLTA	Ribosome (RB)	Undisclosed	[12]
ADC Info	TAK-573	Attenuated form of IFN alpha	Interferon alpha-1/13 (IFNA1; IFNA13)	Undisclosed	[13]
ADC Info	Anti-CD38 IT OKT10-SAPORIN	Saporin	Microtubule (MT)	Undisclosed	[14]

References

Ref 1	An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers
Ref 2	Introduction to basic information on ADC drug CD38 ADC
Ref 3	CD38 antibody-drug conjugates
Ref 4	EDC technology company product EDC8
Ref 5	Introduction to basic information on ADC drug AA-A225
Ref 6	Neodegrader conjugates; 2021-10-07.
Ref 7	ValCitGlyPro-dexamethasone antibody conjugates selectively suppress the activation of human monocytes
Ref 8	Directed conjugation technology
Ref 9	Antibody-drug complexes containing hemiasterlin derivatives
Ref 10	Pharmaceuticals containing antibody-drug complexes containing hemiasterin derivatives
Ref 11	Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies. Blood. 2019 ;134():-. doi: 10.1182/blood-2019-132062.
Ref 12	TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma. Cancer Res (2019) 79 (13_Supplement): 2384.
Ref 13	TAK-573, an Anti-CD38/Attenuated Ifn Fusion Protein, Has Clinical Activity and Modulates the Ifn Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma. Blood (2020) 136 (Supplement 1): 37-38. doi: 10.1182/blood-2020-141219.
Ref 14	Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Br J Cancer. 2001 Feb;84(4):571-8. doi: 10.1054/bjoc.2000.1633.

Antigen Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)